Atossa Therapeutics Welcomes Michael Parks as VP of Investor Relations
Atossa Therapeutics, Inc. (Nasdaq: ATOS) has announced the appointment of Michael Parks as the new Vice President of Investor and Public Relations. With nearly 30 years of experience in investor relations and corporate communications, Mr. Parks has worked extensively within the biopharmaceutical and healthcare sectors worldwide. In his new role, he will manage corporate, executive, and digital communications, as well as investor relations, thought leadership, and branding for the company. Atossa is a clinical-stage biopharmaceutical firm focused on developing groundbreaking medicines to address significant unmet medical needs in oncology, particularly breast cancer.
Michael Parks' Expertise
“We are thrilled to have Michael join Atossa,” stated Steven Quay, M.D., Ph.D., President and Chief Executive Officer of Atossa. “He is an experienced corporate communications professional with a wealth of knowledge across healthcare companies of various sizes and stages. His extensive background and multifaceted approach to communications will greatly benefit Atossa as we work to highlight the tremendous potential of the (Z)-endoxifen platform for patients and translate this opportunity into value for our investors and stakeholders.”
Professional Background
Before joining Atossa, Mr. Parks served as Vice President of Investor Relations at PAVmed, a diverse commercial-stage medical technology company involved in medical devices, diagnostics, and digital health. He also worked with its publicly traded subsidiary, Lucid Diagnostics, a cancer prevention medical diagnostics company. Previously, Mr. Parks led corporate communications and public affairs at Liquidia Corporation. He founded and presided over Pitch360, a consulting firm that offered comprehensive investor relations, corporate communications, and public affairs services to private and small-cap biopharmaceutical companies. Earlier in his career, he held the position of Vice President of Corporate Communications at Centocor, a Johnson & Johnson Company, and took on increasing responsibilities at Pfizer, Pharmacia, and Searle Pharmaceuticals.
Michael Parks' Vision for Atossa
“I am excited to join Atossa at such a crucial moment in the company’s journey,” Mr. Parks remarked. “Atossa’s dedication to advancing innovative therapies in oncology, especially in breast cancer, resonates with my passion for sharing impactful stories with the healthcare, investor, and patient communities. I eagerly anticipate working alongside this committed team to enhance value and awareness among Atossa’s diverse stakeholders.”
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines to meet significant unmet medical needs in oncology, with a primary emphasis on breast cancer and lung injury resulting from cancer treatments.
Frequently Asked Questions
Who is Michael Parks?
Michael Parks is the newly appointed Vice President of Investor and Public Relations at Atossa Therapeutics, bringing nearly 30 years of experience to the role.
What will Michael Parks oversee at Atossa?
He will be responsible for corporate, executive, and digital communications, as well as investor relations, thought leadership, and branding for the company.
What is Atossa Therapeutics' main focus?
Atossa is dedicated to developing innovative medicines aimed at addressing significant unmet medical needs, particularly in oncology and breast cancer.
What did Steven Quay say about Michael Parks?
Steven Quay expressed enthusiasm about Michael’s appointment, emphasizing his extensive experience in corporate communications across various healthcare sectors.
What is Michael Parks' vision at Atossa?
Mr. Parks aims to advance innovative therapies in oncology while enhancing communication with the healthcare, investor, and patient communities.
